Non- Alcoholic Steatohepatitis - Pipeline Review, H2 2012



Global Markets Direct

$ 2000

In Stock

NonAlcoholic Steatohepatitis Pipeline Review, H2 2012

Global Markets Directs, 'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2012', provides an overview of the Non-Alcoholic Steatohepatitis therapeutic pipeline. This report provides information on the therapeutic development for Non-Alcoholic Steatohepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Alcoholic Steatohepatitis. 'Non-Alcoholic Steatohepatitis Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • A snapshot of the global therapeutic scenario for Non-Alcoholic Steatohepatitis.
  • A review of the Non-Alcoholic Steatohepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Non-Alcoholic Steatohepatitis pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Non-Alcoholic Steatohepatitis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. 
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Non-Alcoholic Steatohepatitis pipeline depth and focus of Non-Alcoholic Steatohepatitis therapeutics. 
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Non-Alcoholic Steatohepatitis Therapeutic Products under Development, Key Players in Non-Alcoholic Steatohepatitis Therapeutics, Non-Alcoholic Steatohepatitis Pipeline Overview, Non-Alcoholic Steatohepatitis Pipeline, Non-Alcoholic Steatohepatitis Pipeline Assessment